SEC Form 4 · accession 0001493152-18-003194
INTERPACE BIOSCIENCES, INC. · IDXG
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Jack E Stover
Officer — President and CEO · Director
Period of report
Mar 7, 2018
Accepted (ET)
Mar 9, 2018 · 5:32 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001054102
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1,F2,F3 | Mar 7, 2018 | A | 56,000 | — | A | 75,738 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (right to buy)F4 | $1.01 | Mar 7, 2018 | A | 224,000 | A | — | Mar 7, 2028 | Common Stock | 224,000 | 224,000 | D |
Explanation of responses
- F1The restricted units vest annually, in equal installments, over a three-year period, commencing on March 7, 2019.
- F2Each restricted unit represents the contingent right to receive one share of common stock of Interpace Diagnostics Group, Inc. (the "Issuer").
- F3Reflects 1-for-10 reverse stock split, effective as of December 28, 2016.
- F4The option award vests and becomes exercisable over a three-year period, in equal installments, commencing on March 7, 2019, subject to the reporting person's continued service with the Issuer.